30 Stocks Moving in Monday's Pre-Market Session

Gainers

• vTv Therapeutics Inc. VTVT rose 57.1% to $3.30 in pre-market trading after the company reported the results from part 2 of the Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction in HbA1c.
• Mereo BioPharma Group plc MREO shares rose 27.4% to $2.00 in pre-market trading. Mereo BioPharma reported a $5 million convertible equity financing with Novartis and disclosed a securities purchase deal with Aspire Capital Fund for up to $28 million.
• Valeritas Holdings, Inc. VLRX rose 24% to $0.79 in pre-market trading after the company announced an agreement for Zealand Pharma to acquire business and retain employees.
• Adverum Biotechnologies, Inc. ADVM shares rose 22.7% to $12.56 in pre-market trading after the company reported the interim data from the Cohorts 1 and 2 of OPTIC Phase 1 trial of ADVM-022 intravitreal gene therapy showed robust efficacy with evidence of a dose-response. Cantor Fitzgerald upgraded Adverum Biotechnologies from Neutral to Overweight and raised the price target from $8 to $21.
• Onconova Therapeutics, Inc. ONTX rose 15.3% to $0.5650 in pre-market trading after climbing 12.28% on Friday.
• Tesla, Inc. TSLA rose 9% to $814.89 in pre-market trading following an article suggesting Google could acquire the company for $1500 per share which could raise Tesla's market cap to $1.5 trillion.
• EQM Midstream Partners, LP EQM rose 7.1% to $23.67 in pre-market trading.
• L Brands, Inc. LB shares rose 6% to $25.00 in pre-market trading following news the company is nearing a deal to sell its Victoria's Secret brand to private equity firm Sycamore Partners.
• The Macerich Company MAC rose 5.4% to $24.61 in pre-market trading after declining 6.26% on Friday.
• Inovio Pharmaceuticals, Inc. INO shares rose 5.1% to $3.35 in pre-market trading after the company received authorization from the U.S. FDA to begin Phase 1/2 clinical trial for INO-3107 to treat recurrent respiratory papillomatosis.
• GameStop Corp. GME shares rose 5% to $4.00 in pre-market trading after falling 8% on Friday.
• Protalix BioTherapeutics, Inc. PLX rose 4.9% to $3.65 in pre-market trading.
• Martin Midstream Partners L.P. MMLP rose 4.3% to $2.71 in pre-market trading.
• Futu Holdings Limited FUTU rose 3.9% to $11.80 in pre-market trading.
• Trillium Therapeutics Inc. TRIL rose 3.4% to $3.98 in pre-market trading.
• Micro Focus International plc MFGP rose 3.4% to $10.27 in pre-market trading.
• Moderna, Inc. MRNA rose 3.3% to $24.00 in pre-market trading after surging 16.90% on Friday.
• Invitae Corporation NVTA rose 3.3% to $23.75 in pre-market trading. Invitae is expected to release Q4 results on February 19.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Check out these big penny stock gainers and losers

Losers

• Acasti Pharma Inc.ACST fell 30% to $0.5299 in pre-market trading after the company issued an update on TRILOGY 1 and TRILOGY 2 Phase 3 trials of CaPre.
• Biohaven Pharmaceutical Holding Company Ltd. BHVN fell 16.1% to $43.00 in pre-market trading after the company reported that troriluzole study for generalized anxiety disorder missed primary endpoint.
• Benitec Biopharma Limited BNTC shares fell 10.5% to $6.66 in pre-market trading after jumping 40.64% on Friday.
• Yield10 Bioscience, Inc. YTEN fell 10.1% to $7.80 in pre-market trading after declining 17.33% on Friday.
• Borr Drilling Limited BORR fell 7.5% to $4.35 in pre-market trading.
• My Size, Inc. MYSZ fell 5.8% to $2.49 in pre-market trading after rising 9.58% on Friday.
• Eli Lilly and Company LLY fell 4.5% to $139.85 in pre-market trading after the company reported the results for Solanezumba from the Alzheimer's study did not meet its primary endpoint.
• Viomi Technology Co., Ltd VIOT fell 4.5% to $7.20 in pre-market trading.
• Xunlei Limited XNET fell 4.4% to $4.09 in the pre-market trading session.
• Honda Motor Co., Ltd. HMC fell 3.4% to $25.60 in pre-market trading. Honda Motor reported Q3 results on Friday.
• Myriad Genetics, Inc. MYGN fell 3.3% to $20.33 in pre-market trading. Myriad Genetics shares tumbled over 28% on Friday after the company reported worse-than-expected Q2 EPS and sales results.
• Biogen Inc. BIIB shares fell 3.3% to $327.69 in pre-market trading.